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Abstract As more and more cell and gene therapies
are being developed and with the increasing number of
regulatory approvals being obtained, there is an
emerging and pressing need for industrial translation.
Process efficiency, associated cost drivers and regu-
latory requirements are issues that need to be
addressed before industrialisation of cell and gene
therapies can be established. Automation has the
potential to address these issues and pave the way
towards commercialisation and mass production as it
has been the case for ‘classical’ production industries.
This review provides an insight into how automation
can help address the manufacturing issues arising from
the development of large-scale manufacturing pro-
cesses for modern cell and gene therapy. The existing
automated technologies with applicability in cell and
gene therapy manufacturing are summarized and
evaluated here.
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Introduction
Cell and gene therapies are medicinal products that
utilise cells and genes to treat disease. These new
therapeutics are the next frontier of medicine with
unlimited potential, but also with numerous challenges
still to overcome until affordable and safer products
are available.
According to the database of the US National
Library of Medicine (US Department of Health &
Human Services 2017), there are currently more than
33,000 cell and gene therapy clinical trials worldwide
to date, either ongoing or completed. However, only a
small proportion of these (12 in Europe and 17 in US)
have received marketing approval to date (EMA 2018;
US Food and Drug Administration 2017). This could
be due to many challenges related to manufacturing
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that are still to be addressed. Marketing and regulatory
approval of advanced therapies have two main
requirements: (1) to demonstrate the safety and
efficacy of the therapy in treating the targeted disease
(de Wilde et al. 2018) and (2) to demonstrate
consistent and rigorous manufacturing to a well-
defined product quality (Morrow et al. 2017). Automa-
tion has the potential to address many of these existing
challenges, while facilitating the requirements for
regulatory and marketing approval. This review will
cover the current requirements for manufacturing cell
and gene therapies, the added value of automation and
the existing automated technologies.
Cell and gene therapy manufacturing
requirements
The current manufacturing processes for cell and gene
therapies are largely manual, mostly performed in
planar culture systems. These are highly laborious,
often involve open processes which are difficult to
scale-up and rely heavily on the operator’s experience
and judgement. As a consequence, they are prone to
human error and they can result in increased batch-to-
batch variability, high manufacturing costs, increased
risk of contamination and batch loss.
Cell and gene therapies typically rely on patient or
donor cells as starting material for their manufacture
which determines significant batch-to-batch variation
inherent to the complexity of the biological product
(Heathman et al. 2016). When manufacturing such
highly complex products, it is highly important to
acknowledge that any change, regardless of how
minor in the culture environment as determined by the
manufacturing process may result in the alteration of
product quality which is a key determinant of its safety
and efficacy (Morrow et al. 2017). In order to comply
with these requirements, it is suggested that the
manufacturing process should be simple enough to
allow reproducibility and of a short duration to
minimise costs associated with resources and labour
(Masri et al. 2017).
What is more is that cell and gene therapy products
are not only highly complex, but at the same time, they
have to comply with the strict regulatory framework.
There is a requirement that these cell-based products are
produced in accordance with good manufacturing
practise (GMP) which will minimise process variability
and therefore variation in cell quality. GMP compliance
can be achieved when consistent GMP-grade materials
from well-characterised sources are utilised (Medicine
Manufacturing Industry Partnership 2016). However
fullGMP-compliance in the cell and gene therapy realm
is currently challenging, particularly because of the
increased difficulty in sourcing compliant starting
material. This challenge is exacerbated when taking
into account the variability associated with manufac-
turing patient-specific therapies (autologous) where the
donor is the diseased patient which means that cell
quality will not be of the required standard.
In contrast to ‘traditional’ biopharmaceutical pro-
duction where processes are based on one, well
characterized strain and can be repeated relatively
well, cell and gene therapy manufacturing processes
require increasingly adaptive process strategies that
take the inherent variability of the living product into
account. This can be achieved through a tight control
over product quality attributes that can only be reached
through an increased level of control over process
parameters. Extensive online process monitoring and
integrated control are required as they provide a
crucial tool for process characterization and for
detection and adaptation to process changes (Cierpka
et al. 2013). However, basic knowledge of links
between various parameters and process outcomes is
often missing as it is difficult to define what needs to be
measured and when. In addition, kinetics and balances
in such complex biological systems are difficult to
determine and describe. This inevitably makes con-
trol, reproducibility and repeatability of this kind of
bioprocesses challenging. In this respect, better pro-
cess monitoring could accelerate process development
and improve production efficiency, while ensuring
high-quality endpoint products (Rodrigues et al.
2011). Furthermore, documentation of process data
is necessary to obtain regulatory approval (Cierpka
et al. 2013) and approved release criteria.
Traditionally, post processing quality control (QC)
is applied in the pharmaceutical industry to verify if
the final product meets the set quality standards.
However, when applied to the cell and gene therapy
industry, this approach can be inadequate as these
products encompass an inherent higher level of risk
and variability whilst also being indication specific. A
quality by design approach (QbD) would be more
appropriate for the manufacture of these complex
products, especially when it is the cell itself that is the
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product (Lipsitz et al. 2016). To this end, the field is
moving towards a higher level of process understand-
ing with more sophisticated real-time monitoring and
control as well as the incorporation of advanced
automated systems.
The added value of automation
Automation can provide more control over a bioprocess
through the use of sensors that produce online and
continuous measurements, while leading to a more
accurate and faster process optimization. Besides
biological variation which is difficult to tackle due to
the complexity of these products, in-process variation
occurring from human handling is another persistent
issue that can impact product quality. Even when
stringent protocols are used, variation is observed
between different handlers as a result of minor impre-
cisions in protocols (e.g. slight deviations in incubation
times, variation in pipetting etc.). Automation can
eliminate in-process variation through the use of robotic
arms that can repeatedly and consistently perform a
pipetting or a mixing action or even a whole cell culture
sub-process (e.g. medium change) with consistent
speed, force and accuracy, thus leading to reduced
variability and increased process reliability.
Process parameters, settings and timing can be
exactly determined, saved and tracked. Moreover,
integration and automation of process analytics can
eliminate the subjectivity of the judgments on which
processing decisions are currently based and thus more
sophisticated processing rules are made possible. For
example, development of pattern recognition and image
processing software can be used to objectively deter-
mine confluence. Cell culture protocols rely on passag-
ing cells when they reach a confluence level of 70–80%.
Confluency is typically estimated through microscopic
visualisation of the cell culture and the percentage
estimation is entirely subjective and dependent on the
operator. The employment of automated image acqui-
sition and processing can lay the foundation for
adaptive processing based on objective and compre-
hensible criteria (Schenk et al. 2015). Additionally,
automation can be adapted for increased through-
put/parallelization of systems and it offers an enhanced
possibility to monitor and track data.
In the cell and gene therapy realm, the benefits of
automation could be translated into closed
manufacturing platforms. The existing platforms will
be discussed in the next sections where they are
categorised depending on the level of automation
integrated. Automation can refer to many approaches:
automation of one step alone, integration of several
steps in one machine (1st generation) or fully
automated (2nd generation). It has to be noted here
that the term ‘‘fully automated’’ refers to a platform or
process which apart from eliminating manual opera-
tors for culturing cells, it also eliminates the need for
manual transfer of materials from one-unit operation
to another.
Evolution of automation: from past to future
1st generation automated platforms
The 1st generation of automated systems came to
address the lack of consistency due to manual
handling. They entail the use of robotic arms and
pipetting robots, programmed to imitate human
actions, thus rendering the culturing of cells, more
accurate, reproducible and consistent, while offering
the possibility of processing larger volumes through a
scaled-out approach. The CompacT SelecTTM (Sarto-
rius) is one such system that makes use of an
incubator, robotic arm and peristaltic pumps to carry
out the different steps for cell culture. The CompacT
SelecT has been used in commercial and academic
settings for the subculture and expansion of different
cell types in T-flasks (Soares et al. 2014; Thomas et al.
2009).
The Cellmate system (Sartorius) is another example
that operates under the same principle allowing for
higher volume expansion of cells in roller bottles and
T-flasks without process change. This system is
currently used by ReNeuron for the larger scale batch
manufacture of their CTX stem cell therapies for
stroke, as they move to phase III clinical tri-
als (‘‘ReNeuron to use Cellmate automated cell cul-
ture for stem cell-based stroke therapy—Cambridge
Network’’ 2015). Avigen is another company that
chose the Cellmate platform for manufacturing their
adeno-associated viral vectored gene therapy product
for clinical trials (‘‘Cellmate—System Overview’’
n.d.).
More recently, numerous pipetting and liquid
handling automated systems have emerged for the
123
Biotechnol Lett (2019) 41:1245–1253 1247
automation of laborious tasks, possibility to scale
down or to increase the throughput. Examples include
CyBio (Analytik Jena), RoboLector (M2P Labs)
(Kensy et al. 2009), CelloTM robot (Sartorius),
Biomek 4000 (Beckman), Freedom EVO (Tecan),
STAR system (Hamilton), SimCellTM. (Lindgren et al.
2009; Warr et al. 2009) These systems have been used
successfully for cell culture applications (US Food and
Drug Administration 2017), cell line development
(Deng et al. 2011; Lindgren et al. 2009), cell
characterisation or even for nanoscale assay develop-
ment (Mosquito - TTP Labtech) (Goadsby et al.
2017). However none of these systems are fully
automated platforms capable of supporting a biopro-
cess from start to finish.
Another platform that was developed under the
same principle is BioLector (M2P Labs) which
provides a micro-fermentation system able to contin-
uously monitor growth and fluorescence of recombi-
nant reporter proteins under defined conditions in
microtiter plates, incorporating online integrated ana-
lytics. This platform is suitable for downscaling and
process development. However, there were no reports
of using this platform with human cells, but only with
bacterial or yeast cells (Back et al. 2016; Funke et al.
2010).
While the aforementioned platforms are suited for
automated plate-based processes in high-throughput,
they have limited applicability for cell and gene
therapy production due their poor scalability and
transferability to stirred tank systems. Consequently,
platforms such as the Ambr15 and Ambr250
(Sartorius) revolutionized process development by
introducing high-throughput options for cell culture,
while using single use, disposable bioreactor vessels in
an automated processing setting using an automated
liquid handler. These platforms have been proven very
useful for scale down studies and process development
(Ryder et al. 2016). Both platforms make use of
disposable pH and DO sensors, allowing for a better
process control and facilitating scale-up of processes.
Moreover, platforms such as these have been devel-
oped and adapted for culture of both suspension and
adherent cells when grown on microcarriers (Nienow
et al. 2013; Rafiq et al. 2017).
All of these systems come with advantages and
disadvantages (Table 1). For example, systems such as
the Ambr15 (Sartorius), STAR (Hamilton) and the
Freedom EVO (Tecan) only accept manufacturer’s
compatible pipette tips and specifically designed
vessels, thus limiting their flexibility. Other limita-
tions are related to the system’s functionality. For
example, the STAR system (Hamilton) is only able to
pipette small volumes at a time (5 mL), while the
Ambr15 system is limited by the minimum agitation
speed that can be employed (and hence minimum local
energy dissipation rates), thus limiting its applicabil-
ity. The CompacT SelecT (Sartorius), although suit-
able for adherent cell culture does not incorporate a
centrifuge, thus the centrifugation step required for
subculturing cells has to be performed outside the
platform.
In general, most of these liquid handling robots
have large footprints, are expensive and require high
servicing and maintenance costs. Additionally, they
lack flexibility and they rely on additional pieces of
equipment (e.g. centrifuge, incubator etc.) to carry out
the workflow. They often require manufacturer speci-
fic consumables and their performance is highly
dependent on the operator’s programming skills.
However, robotic platforms can prove to be very
useful for cell culture applications as they allow
robustness and reliability and they minimise process
variability by limiting the human error.
2nd generation automated platforms
Unlike the 1st generation, the 2nd generation of
automated systems will allow for reduced manual
handling as they offer complete automation on a
sequence of operational units instead of only one. For
example, these platforms would have the capability to
receive donor tissue at one end and to offer a ‘polished
product’ ready for distribution at the other end. These
platforms will provide continuous process validation
and monitoring which could enable better process
understanding and faster optimisation. They would be
fully closed integrated platforms, thus eliminating
human contact with the source material or the cell
product during processing. This would de-risk the
production process by eliminating contamination,
human error and would simplify the process by most
likely rendering the use of clean rooms obsolete, thus
minimising overall manufacturing costs. These plat-
forms would be fully integrated, yet modular, allowing
for flexibility which is key to the ever-evolving field of
cell and gene therapy manufacturing.
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An example of such a platform is represented by the
CliniMACS Prodigy system (Miltenyi Biotech) that is
a commercially available, fully integrated platform
dedicated to autologous cell and gene therapy manu-
facturing. This platform allows for cell activation,
transduction, amplification and final harvesting
through unit operations such as cell enrichment via
optimisation of cell surface markers, centrifugation
and cultivation, all performed in one device. The
CliniMACS Prodigy platform is equipped with inte-
grated IPC/QC sampling pouches that allow the option
to sample without opening the system by disconnec-
tion through sterile welding. Customisation of proto-
cols is achieved through modularity and flexible
programming, thus permitting its use for a variety of
different cell types from the expansion of CAR-T
cells, virus-specific T-cells, macrophages through to
dendritic cells (Fraser et al. 2017; Mock et al. 2016;
Zhu et al. 2016, 2019). For these reasons, the
CliniMACS Prodigy platform was approved by the
European Medicinal Agency (EMA) for the commer-
cial manufacturing process of an already approved
therapy e.g. Zalmoxis (MolMed) (Gladbach et al.
2018). However, this platform is only applicable to
suspension cells and has not been tested to date for its
suitability on isolating and expanding adherent cells.
To this extent, it is limited in its applicability and not
highly versatile. Additionally, this platform is limited
to a patient-specific (i.e. autologous) approach, mainly
due to the processing volumes of up to 400 mL. To
develop an allogeneic therapy, multiple such plat-
forms would be required to run in parallel through a
scale-out rather than scale-up approach. Lastly, this
all-in-one approach may create significant manufac-
turing issues as although the transduction step is
performed in a matter of hours, the cell expansion
requires many days, thus creating a bottleneck in
manufacture by limiting the use of the platform to one
Table 1 Advantages and disadvantages of 1st generation automated cell culture systems
Culture
system
Manufacturer Advantages Limitations
Freedom
EVO
Tecan – High precision
– Allows for effective speeding up of processing
– Offers liquid detection and notification for particles
obstructing the pipetting
– Requires specific consumables
– Requires special training for its
programming and utilising fully the
software’s capabilities
STAR Hamilton – High precision pipetting at small volumes
– Modular design allowing for expansion as needs grow
– Requires specific consumables
– Handles small volumes (\ 5 mL) at a
time
CompacT
SelecT
Sartorius – Suitable for both adherent and suspension cell culture
– Ability to process up to 90 T175 flasks and 384 well
plates
– Runs subculture, cell counting and harvesting
– Requires additional pieces of equipment
(e.g. centrifuge, microscope) to carry out
the workflow
– Large footprint
Biomek
4000
Beckman
Coulter
– Provides accuracy at handling small volumes – Requires specific consumables
RoboLector M2P labs – Includes preparation of media
– Allows for pH adjustments
– Volumes higher than 950 lL are pipetted
in 2 steps
Cellmate TAP
Biosystems
– Using both flasks and roller bottles – Does not incorporate automated
harvesting
CyBio Analytik
Jena
– Full assay automation including preparation of assay
plates and measurements, cell seeding and incubator
for further culture
– Only takes microplates
– Requires specific consumables
Ambr15
and
Ambr250
Sartorius – Proven scale down models
– High throughput
– Ability to run multiple conditions simultaneously
– Suitable for optimisation studies
– Require specific consumables
– Limited agitation speed range
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patient at a time and for a significant period of time,
inevitably resulting in high manufacturing costs.
Similarly, another ‘device-based’ production plat-
form targeting autologous cell therapies is the
CocoonTM (Octane Biotech Inc.) which is an all-in-
one, closed, non-agitated, fully automated platform
that enables several operational units to be performed
within a single chamber. The capabilities of this
platform are: cell seeding, expansion, perfusion,
digesting/harvesting, concentration, washing and for-
mulation. However, similarly to the CliniMACS
Prodigy, this platform is also limited to the CAR-T
cell space and has not been tested for adherent cell
culture (Iyer et al. 2018).
Another closed, automated system tested for both
adherent and suspension cell culture is the QuantumTM
(Terumo BCT). This platform is essentially a hollow
fibre bioreactor that contains single-use cartridges,
providing a surface area of 2.1 m2 per cartridge (Iyer
et al. 2018). The QuantumTM has been successfully
tested with adipose derived stromal cells (ASCs), bone
marrow derived mesenchymal stromal cells
(BMMSC) and neural stem cells (Haack-Sørensen
et al. 2016; Martin-Manso and Hanley 2005). The
Quantum only comprises of a bioreactor which limits
its use to cell expansion only. This platform is not
versatile enough to allow for other bioprocess
enhancements such as cell enrichment or isolation
from donor tissue.
More recently, through European research initia-
tives, a series of fully automated platforms capable of
supporting the bioprocess from start to finish were
developed. One such example is the Stem Cell Factory
(Marx et al. 2013) that is a fully automated production
unit for reprogramming, cultivation and differentia-
tion of induced pluripotent stem cells (iPSCs). Its
capability is up to 60 different iPSC lines in parallel.
However, one versatile platform recently devel-
oped that would allow for a fully automated manu-
facturing and banking of cell therapies undertaking a
donor-to-patient approach is the AUTOSTEM fully
automated platform (Fig. 1). AUTOSTEM allows for
tissue collection, isolation, cell expansion, harvest,
concentration and cryopreservation of cell-based
products. It is a fully enclosed, GMP-ready platform
that comprises of a pipettor, robotic arms and propri-
etary technology in the unique design of grippers that
allows versatility and flexibility in handling a variety
of culture vessels (e.g. tubes, cryovials) for the
different steps of the process. The AUTOSTEM
platform was tested with human mesenchymal stem/
stromal cells, however its modularity and flexibility
allows for adaptation to other adherent cell types and
even suspension cells, thus expanding its applicability
and versatility (Callens et al. 2016; Murphy et al.
2017; Ochs et al. 2017).
These platforms offer the equivalent of a GMP
manufacturing environment and are relevant for bench
to bedside applications. The fully closed environment
that these platforms provide is equivalent to a clean
room environment, while the automation (in the form
of robotic arms and control units) is equivalent or
better than the highly trained personnel employed in
GMP facilities. The GMP certified equipment remains
the same, but it is now enclosed within a Class II
cabinet using an automated platform and with LOG
files produced and stored electronically during the
process which forms the basis of the QM documen-
tation required for every GMP manufacturing process.
Even if still under development, both the AUTO-
STEM and the Cocoon systems offer more versatility
than the existing platforms as they incorporate
advanced bioreactor and scaffold technology coupled
with complete automation of the different operational
units required, with applicability in both adherent and
suspension cell culture. Both systems receive patient
tissue and perform the isolation of the targeted cells,
followed by their expansion and quality control, all
inside the enclosed platform, delivering cryovials of
frozen cells or a living scaffold implant at the end of
the process, while only requiring minimum manual
handling for the loading of the consumables to the
platform. In the case of the AUTOSTEM platform, an
additional advantage is that loading of the tissue
sample (i.e. the bone marrow) is also performed
automatically as the bone marrow suction device is
integrated into the platform. Analytics in the form of
multiple capability sensors can also be integrated,
further minimising the risk of contamination and
improving culture monitoring capabilities (Murphy
et al. 2017).
Another important advantage that these 2nd gener-
ation automated cell manufacturing platforms intro-
duce to the field is the increased flexibility and
modularity. Hardware modules are integrated in the
platform via agents into the control software using a
plug-and-produce approach and software that is
adaptable to different applications (i.e. different
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process conditions or different cells). This is important
as the field is continually evolving and the added
complexity of bioprocesses using living cells will
always be there, as biological processes are far from
being understood or predicted to the same extent as
chemical processes currently are (Jung et al. 2018).
Conclusions and outlook
While the advanced therapy manufacturing is already
profiting from automation approaches that have been
used successfully in the ‘traditional’ production
industries for a long time, it does not yet fully exhaust
the potential of advanced manufacturing approaches
which are currently being developed by the industry
4.0 (Kulik et al. 2016).
Automation and enabling technologies such as
digitalisation, process analytical technologies and data
processing have the potential to change the way we
develop and produce cell and gene therapies. These
new fully automated platforms (2nd generation) will
provide a better understanding of the impact that
processes might have on cell quality, while delivering
enhanced reproducibility, facilitate regulatory
compliance and lower manufacturing costs through
optimised bioprocesses. By removing the manual
handling completely, the safety and efficacy of the
cell-based products will be enhanced. In the long term,
automation can be the enabler of cost reduction,
paving the way towards a broad application of cell and
gene therapies as first-option treatments, while offer-
ing better accessibility for the patients.
To take this further, the next generation of
automated cell manufacturing systems could poten-
tially include artificial intelligence and machine
learning tools. These could prove very helpful for
process optimization and could minimize the chal-
lenges imposed by biological variability by revealing
patterns and correlations between certain biological
characteristics and process outcomes. This could
potentially pave the way to a different approach for
autologous therapies; for example, identifying donor
material as a critical control point during the biopro-
cess and by incorporating a quality control step on the
harvested tissue could help to further de-risk the
process by making predictions on the outcome and
effectiveness of the bioprocess.
Fig. 1 The AUTOSTEM platform
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